尽管人们对 Prime Medicine 的基因编辑技术感兴趣，但其股票面临褒贬不一的评价。 Prime Medicine's stock faces mixed reviews despite interest in its gene editing technology.

分析师对 Prime Medicine 的股票建议不一，一些人下调了目标价，但维持买入评级。 Prime Medicine's stock has seen mixed analyst recommendations, with some lowering price targets but maintaining buy ratings. 尽管StockNews.com公司有Q4 EPS的失误和最近的“销售”升级, 该公司仍保持其他公司的积极评级。 Despite a Q4 EPS miss and a recent "sell" upgrade from StockNews.com, the company retains positive ratings from other firms. 以利用基因编辑技术进行基因疗法为重点的初级医学面临收入预测降级,但继续吸引机构投资者的兴趣。 Prime Medicine, focused on genetic therapies using gene editing technology, faces downgraded earnings forecasts but continues to attract institutional investor interest.